NASDAQ:RCKT

Rocket Pharmaceuticals (RCKT) Stock Price, News & Analysis

Rocket Pharmaceuticals logo
$2.16 -0.14 (-6.09%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$2.24 +0.08 (+3.75%)
As of 11/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Rocket Pharmaceuticals Stock (NASDAQ:RCKT)

Advanced

Key Stats

Today's Range
$2.15
▼
$2.35
50-Day Range
$2.16
▼
$3.71
52-Week Range
$2.15
▼
$5.45
Volume
1.92 million shs
Average Volume
1.66 million shs
Market Capitalization
$237.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.77
Consensus Rating
Hold

Company Overview

Rocket Pharmaceuticals, Inc. is a biotechnology company developing gene therapies for rare, serious diseases, with a focus on inherited disorders that often affect children. Its research programs use lentiviral and adeno-associated viral (AAV) vector technologies to deliver therapeutic genes to patients’ cells.

The company’s pipeline has included programs targeting conditions such as Fanconi anemia, leukocyte adhesion deficiency-I, pyruvate kinase deficiency, Danon disease and arrhythmogenic cardiomyopathy. Rocket conducts research and clinical development from its base in Cranbury, New Jersey, and works to advance its therapies through clinical testing and regulatory review.

AI Generated. May Contain Errors.

Rocket Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
66th Percentile Overall Score

RCKT MarketRank™: 
3.31914327524 of 5 stars

Rocket Pharmaceuticals scored higher than 66% of companies evaluated by MarketBeat, and ranked 265th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Rocket Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.42, and is based on 1 strong buy rating, 5 buy ratings, 4 hold ratings, and 2 sell ratings.

  • Upside Potential

    Rocket Pharmaceuticals has a consensus price target of $7.77, representing about 259.8% upside from its current price of $2.16.

  • Amount of Analyst Coverage

    Rocket Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Rocket Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Rocket Pharmaceuticals are expected to decrease in the coming year, from ($1.36) to ($1.44) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Rocket Pharmaceuticals is -14.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Rocket Pharmaceuticals is -14.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Rocket Pharmaceuticals has a P/B Ratio of 0.84. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    18.80% of the float of Rocket Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Rocket Pharmaceuticals has a short interest ratio ("days to cover") of 9.07.
  • Change versus previous month

    Short interest in Rocket Pharmaceuticals has recently decreased by 0.24%, indicating that investor sentiment is improving.
  • Dividend Yield

    Rocket Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Rocket Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    Rocket Pharmaceuticals has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Rocket Pharmaceuticals this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    3 people have added Rocket Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Rocket Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $277,472.00 in company stock.

  • Percentage Held by Insiders

    21.30% of the stock of Rocket Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    98.39% of the stock of Rocket Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Rocket Pharmaceuticals' insider trading history.
Receive RCKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RCKT Stock News Headlines

Rocket Pharmaceuticals Inc (RCKT)
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
Transcript : Rocket Pharmaceuticals, Inc. - Special Call
See More Headlines

RCKT Stock Analysis - Frequently Asked Questions

Rocket Pharmaceuticals' stock was trading at $3.51 at the beginning of 2026. Since then, RCKT shares have decreased by 38.5% and is now trading at $2.16.

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) announced its quarterly earnings results on Thursday, November, 12th. The biotechnology company reported ($0.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by $0.03.

Rocket Pharmaceuticals (RCKT) raised $94 million in an IPO on Friday, February 6th 2015. The company issued 6,700,000 shares at $13.00-$15.00 per share.

Top institutional investors of Rocket Pharmaceuticals include Marshall Wace LLP (3.20%), State Street Corp (1.71%), Jump Financial LLC (0.38%) and Ieq Capital LLC (0.16%). Insiders that own company stock include Gaurav Shah, Martin Wilson, Christopher James Stevens, Gotham Makker, Sarbani Chaudhuri, Jonathan David Schwartz, Aaron Ondrey, David P Southwell, David P Southwell, John Militello, Mark Andrew White, Elisabeth Bjork and Kinnari Patel.
View institutional ownership trends
.

Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Rocket Pharmaceuticals investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Pfizer (PFE), Micron Technology (MU), Alibaba Group (BABA), Tesla (TSLA) and Intel (INTC).

Company Calendar

Last Earnings
11/12/2026
Today
11/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:RCKT
CIK
1281895
Employees
202
Year Founded
2018

Price Target and Rating

High Price Target
$15.00
Low Price Target
$2.95
Potential Upside/Downside
+259.8%
Consensus Rating
Hold
Rating Score (0-4)
2.42
Research Coverage
12 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.15)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$223.12 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-53.25%
Return on Assets
-45.31%

Debt

Debt-to-Equity Ratio
0.05
Current Ratio
9.24
Quick Ratio
9.24

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.56 per share
Price / Book
0.84

Miscellaneous

Outstanding Shares
109,780,000
Free Float
86,393,000
Market Cap
$237.12 million
Optionable
Optionable
Beta
0.51

Social Links

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NASDAQ:RCKT) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners